Cure Cdkl5 Foundation
Nonprofit profile at a glance
- EIN
- 881224505
- IRS 990-EZ coverage
- 2022–2025
- Forms available
- Form 990-EZ 2025
- Location
- Manhattan Beach, CA, USA
- Phone
- 3105455400
- Rating confidence
- Limited
- Sector
- Fund Raising and/or Fund Distribution
Reported finances
- Revenue
- $0
- Expenses
- $39
- Assets
- $9,823
Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.
Leadership & pay
1 person listed
Executive titles in this filing
- JESSICA LINDERMAN (President & CEO)
People named in this filing
- JESSICA LINDERMAN (President & CEO)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Cure CDKL5 Foundation, established in Spring 2022, is a nonprofit organization devoted to funding the research and development of treatments and cures for CDKL5 deficiency disorder, a rare form of epilepsy caused by a mutation in the CDKL5 gene. Living with this rare disorder causes a very broad range of clinical symptoms and severity between individuals with the hallmarks being early-onset intractable seizures and neurodevelopmental delays that impact cognitive, motor, speech, and visual functional development. Our mission is to fundraise for CDKL5 specific scientific and clinical research while offering affected CDKL5 families resources to make their individual voyages for a cure more streamlined.
What it reported doing in 2025
2025 was the Third full year the foundation was in operations,
Operating model
- Revenue model
- Cannot be determined from the filing. The filing does not provide enough consistent revenue detail to tell how this nonprofit funds its work.
- Distribution model
- Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.
Rating breakdown
- Financial Efficiency: 38
- Transparency & Controls: 82
- Sustainability: 36
- Growth: 20
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: Limited
- Program expense ratio: 100%; rating input score 100
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 51st percentile among comparable filings
- Major donor itemization: Limited
Sustainability
- Operating margin: Limited
- Total-asset coverage ratio: 251.87; rating input score 100; 100th percentile among comparable filings
- Liabilities to assets ratio: Limited
- Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings
Growth
- Program expense growth: -94% per year; rating input score 0; 4th percentile among comparable filings
- Revenue growth: -45.4% per year; rating input score 0; 7th percentile among comparable filings
- Asset growth: 44.9% per year; rating input score 100; 94th percentile among comparable filings
Details
- Where the money goes: 100% of spending went to programs
- Governance: Filed governance answers
- Accomplishments: 1 filed program accomplishment · $39 in reported program spending
- Leadership: top reported pay $0 · 1 people listed
- Consistency: 6 of 6 current checks pass
- Schedules: 1 filed schedules
- Filing history: 4 filing years from 2022 to 2025
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Growth: Program expense growth scored 0/100.
- High — Growth: Revenue growth scored 0/100.
- Review — Sustainability: Officer compensation ratio scored 56/100.